Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

RVL Pharmaceuticals plc (RVLP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W
1.2500-0.0400 (-3.10%)
At close: 04:00PM EDT
1.1900 -0.06 (-4.80%)
After hours: 04:14PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Performance Outlook
Previous Close1.2900
Open1.3600
Bid1.1500 x 1800
Ask1.2700 x 800
Day's Range1.2500 - 1.3600
52 Week Range0.9800 - 4.3800
Volume98,303
Avg. Volume91,787
Market Cap104.437M
Beta (5Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)-0.8560
Earnings DateAug 15, 2022 - Aug 19, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for RVLP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • RVL Pharmaceuticals plc
    Daily – Vickers Top Buyers & Sellers for 04/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    RVL Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting

    BRIDGEWATER, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the Company’s Annual General Meeting. At the Annual General Meeting of the Company held on June 16, 2022 (the AGM), the resolution placed before the meeting in respect of the approval of the waiver under Rule 9 of the Irish Takeover Rules (the Rules) was duly passed by independent shareholders of the Company on a poll

  • GlobeNewswire

    RVL Pharmaceuticals plc to Present at Upcoming Conferences

    BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will present at two upcoming conferences as follows: H.C. Wainwright Global Investment Conference, Miami Beach, FLDate:Tuesday, May 24, 2022Time:11:00 a.m. ETWebcast:Click Here Jefferies Healthcare Conference, New York City, NYDate:Thursday, June 9, 2022Time:1:30 p.m. ETWebcast:Click

  • GlobeNewswire

    RVL Pharmaceuticals plc Reports First Quarter 2022 Financial Results; Provides Commercial Update

    First quarter 2022 UPNEEQ net product sales of $5.9 million; 90% growth over fourth quarter 2021 First quarter 2022 total revenues of $21.4 million, inclusive of $15.5 million from Santen License Agreement, with related cash receipt in April 2022 Reaffirms fourth quarter 2022 UPNEEQ net product sales guidance of $20 to 25 million UPNEEQ selected as the winner of a “Best in Innovation” award in the 12th Annual Beauty Awards conducted by NewBeauty, a Sandow Publication and “Best Professional Treat

Advertisement
Advertisement